MEDIUM confidence: 100% data completeness, but the composite (51) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Low explanatory power (R² 0.03) — the factor model explains little of this stock's return variation, so these exposures are noisy. Interpret with caution.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $16.1B— | $12.2B-24.3% | $13.1B+7.8% | $14.2B+8.3% | $14.3B+1.0% |
| EPS (dil.) | $71.97— | $38.22-46.9% | $34.77-9.0% | $38.34+10.3% | $41.48+8.2% |
| Free Cash Flow | $6.5B— | $4.4B-32.2% | $3.7B-17.1% | $3.7B-0.1% | $4.1B+11.3% |
| Gross Margin | 83.1% | 86.0%+2.9pp | 82.9%-3.1pp | 86.1%+3.2pp | 85.4%-0.8pp |
| Operating Margin | 55.7% | 44.2%-11.4pp | 33.2%-11.1pp | 28.1%-5.1pp | 24.9%-3.2pp |
| Net Margin | 50.2% | 35.6%-14.6pp | 30.1%-5.5pp | 31.1%+0.9pp | 31.4%+0.3pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Avg target $800 (last qtr, 20 analysts) → $833 (last mo, 7) (+4.1%).
Buy-rated share 74% → 67% over ~3 months (-8pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jul 2026 | $10.16 | $14.29 | +40.6% |
| Apr 2026 | $8.91 | $9.47 | +6.3% |
| Jan 2026 | $10.74 | $11.44 | +6.5% |
| Oct 2025 | $9.65 | $11.83 | +22.6% |
| Aug 2025 | $8.43 | $12.89 | +52.9% |
| Apr 2025 | $8.62 | $8.22 | -4.6% |
| Feb 2025 | $11.21 | $12.07 | +7.7% |
| Oct 2024 | $11.69 | $12.46 | +6.6% |
Net insider -$2.6M over 180 days (0 open-market buys, 48 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth below the analyst consensus of 7.0%/yr (revenue basis).
Base free cash flow $3.8B (avg FY2023–FY2025; latest year $4.1B) · equity value $83.6B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
The QScore of 51 for Regeneron Pharmaceuticals indicates a neutral outlook, with the stock's long-term and short-term scores diverging slightly. The stock scores high on profitability, driven by its strong gross margin and operating margin, as well as a respectable ROE of 13.8%. However, its growth score is somewhat lower, reflecting modest revenue and EPS growth. The stock exhibits strong momentum, with a 12-month return of 45.2%, but trades at a P/E of 19.4, which is relatively in line with its sector.